Skip to Main Content

1,064

Views

28

CrossRef citations to date

0

Altmetric

Original Article: Clinical

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

Jan de JongJanssen Research & Development, San Diego, CA, USA; Correspondence[email protected]
View further author information

,

Peter HellemansJanssen Research & Development, Beerse, Belgium; View further author information

,

Severijn De WildeJanssen Research & Development, Beerse, Belgium; View further author information

,

Daniel PatriciaJanssen Research & Development, Spring House, PA, USA; View further author information

,

Tara MastersonJanssen Research & Development, Spring House, PA, USA; View further author information

,

Georgii ManikhasSt. Petersburg City Oncology Hospital, St. Petersburg, Russian Federation; View further author information

,

Alexander MyasnikovBaranov Republican Hospital, Petrozavodsk, Russian Federation; View further author information

,

Dzhelil OsmanovN.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russian Federation; View further author information

,

Raúl CórdobaSTART Madrid, University Hospital Fundacion Jimenez Diaz, Health Research Institute IIS-FJD, Madrid, Spain; View further author information

,

Carlos PanizoUniversity Clinic of Navarra, Pamplona, Spain; View further author information

,

Loeckie de ZwartJanssen Research & Development, Beerse, Belgium; View further author information

,

Jan SnoeysJanssen Research & Development, Beerse, Belgium; View further author information

,

Vijay ChauhanJanssen Research & Development, Raritan, NJ, USA; View further author information

,

James JiaoJanssen Research & Development, Raritan, NJ, USA; View further author information

,

Juthamas SukbuntherngPharmacyclics LLC, Sunnyvale, CA, USAView further author information

&

Daniele OuelletJanssen Research & Development, Spring House, PA, USA; View further author information